Globus Medical, Inc.

NYSE:GMED

Medical - Devices

Healthcare
$70.53 -2.71%

-$2.10 today

Market cap
$9.34B
Beta
0.95
P/E (TTM)
17.4
EPS (TTM)
$4.33
52W Low $51.79High $101.40

Volume 1.43M

Average 1.45M

GMED EBITDA Margin

EBITDA as a percentage of revenue.

Globus Medical, Inc.NYSE: GMED

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 32.8%

EBITDA Margin was 32.8% in Q2 FY2026, up 6.9 pp from a year earlier. On a trailing-twelve-month basis it was 30.1%, up 6.5 pp year over year. Over 3 fiscal years it widened by 0.4 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 11 analysts of 35.2% for the fiscal year ending Dec 2026, up from 30.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
32.8%+3.0 pp QoQ
Last fiscal yearDec 2025
30.2%+11.4 pp YoY
LTMJun 2026
30.1%+6.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.9 pp+6.0 pp-0.8 pp
1 year+11.4 pp+5.0 pp-6.3 pp
3 years+0.4 pp+4.7 pp+4.2 pp
5 years+4.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
30.2%
Year-over-year change
+11.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GMED compares with its peers on the latest reported figures

  • GMED's LTM Jun 2026 EBITDA Margin of 30.1% is the highest of the 10 companies compared; the peer median is 11.5%.
  • Its year-over-year change of +6.5 pp is the 6th highest of 10, against a peer median of +7.7 pp.
  • Over three fiscal years its change of +0.4 pp compares with a peer median of +5.4 pp.
GMED Competitors Peer median
EBITDA Margin for GMED and competitors
Company Period LTM level YoY 3-year change
GMEDGlobus Medical, Inc.LTM Jun 202630.1% +6.5 pp+0.4 pp
ZBHZimmer Biomet Holdings, Inc.LTM Jun 202627.5% -1.6 pp+5.4 pp
SYKStryker CorporationLTM Jun 202625.9% +5.9 pp+3.4 pp
SNNSmith & Nephew plcFY202521.7% -1.3 pp-0.4 pp
BVSBioventus Inc.LTM Mar 202617.9% +11.6 pp+41.2 pp
OFIXOrthofix Medical Inc.LTM Mar 202611.5% +13.4 pp-6.1 pp
XTNTXtant Medical Holdings, Inc.LTM Mar 20269.7% +12.3 pp+21.2 pp
ATECAlphatec Holdings, Inc.LTM Mar 2026-0.2% +8.0 pp+24.0 pp
KIDSOrthoPediatrics Corp.LTM Mar 2026-2.7% +3.5 pp+2.1 pp
SIBNSI-BONE, Inc.LTM Mar 2026-2.9% +7.7 pp+46.2 pp
Peer median (excluding GMED) 11.5%+7.7 pp+5.4 pp

Competitors are the stored peer set for GMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue958.1M1.02B1.57B2.52B2.94B
Cost of Revenue239.22M263.73M548.17M1.04B957.8M
Gross Profit718.88M759.12M1.02B1.48B1.98B
Gross Margin75.0%74.2%65.1%58.9%67.4%
Research & Development97.35M73.02M124.01M163.75M185M
Selling, General & Admin408.15M432.12M643.41M981.05M1.32B
Operating Expenses546.93M531.17M887.16M1.32B1.5B
Depreciation & Amortization69.87M68.25M144.73M254.02M276.84M
EBITDA264.73M304.5M346.58M473.73M886.74M
EBITDA Margin27.6%29.8%22.1%18.8%30.2%
Operating Income171.95M227.95M133.14M165.99M479.8M
Operating Margin17.9%22.3%8.5%6.6%16.3%
Interest Income9.3M14.23M20.13M07.14M
Interest Expense0004.19M0
Other Income / Expenses8.45M15.07M32.25M(45.27M)130.1M
Income Before Tax180.41M243.02M165.39M120.72M609.9M
Pre-Tax Margin18.8%23.8%10.5%4.8%20.8%
Income Tax Expense31.22M52.85M42.52M17.74M72M
Net Income149.19M190.17M122.87M102.98M537.9M
Net Margin15.6%18.6%7.8%4.1%18.3%
EPS (Basic)1.481.891.090.763.98
EPS (Diluted)1.441.851.070.753.92
Weighted Avg Shares100.73M100.47M113.09M135.73M135.15M
Weighted Avg Shares (Diluted)103.62M102.64M114.63M137.86M137.22M

Globus Medical, Inc.

NYSE:GMED

Intrinsic Alpha fair value

Locked

Current Price

$70.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.